Extroducer Infusion Catheter System
SmartWise Sweden AB · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 11, 2026 for the Extroducer Infusion Catheter System, submitted by SmartWise Sweden AB of Tullinge, Sweden, under 510(k) number K254051. The application was received December 17, 2025 and reviewed under regulation 870.1210 in the Cardiovascular specialty and panel, with classification product code KRA and device classification name Catheter, Continuous Flush. SESE denotes 510(k) clearance, not premarket approval.
The FDA letter excerpt states the system is intended for infusion of diagnostic or therapeutic solutions into the extravascular area, but the excerpt is truncated and the full indication is not available here. The record lists a Traditional summary, no third-party review, no combination product status and no authorized predetermined change control plan. The reviewed summary document and any performance data are not included in the public information, so the basis for the equivalence determination remains unknown.
No component-level change, predicate device or clinical evidence is described in the available text; readers should consult the full K254051 decision documents before drawing clinical or regulatory conclusions.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254051
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- SmartWise Sweden AB
- Product code
- KRA
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Continuous Flush.
- Applicant
- SmartWise Sweden AB
- Product code
- KRA
- FDA device class
- 2
FDA decision timeline
K254051 received
Application receipt date recorded by FDA.
K254051 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KRA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Progreat Lambda 2.1FrK261376 | Terumo Clinical Supply Co., Ltd. | 510(k) clearance | Nov 5, 2026 | FDA |
| Trisalus Life Sciences | 510(k) clearance | Sep 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
SmartWise Sweden AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Tullinge
Sources and methodology
- Original FDA record: K254051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
